Navigation Links
Former Secretary of Veterans Affairs James Peake to Join the Cellphire Board of Directors
Date:6/30/2009

Peake to provide guidance and direction regarding military needs, clinical uses and funding sources

ROCKVILLE, Md., June 30 /PRNewswire/ -- Cellphire, Inc., a biotechnology company located in Rockville, Md., announced today that former Secretary of the Department of Veterans Affairs, James Peake, MD, has joined its board of directors.

"I am excited about the potential of Thrombosomes(R) to save lives on the battlefield and in emergency rooms throughout the US. I am eager to contribute to the effort to conduct appropriate clinical trials to evaluate and ultimately field this product," said Dr. Peake.

Cellphire is committed to developing a freeze-dried platelet product, Thrombosomes(R), which could potentially be effective in stopping uncontrollable bleeding on the battlefield or in trauma. Platelets can only be stored for 5 days and cannot be provided to combat zones, although in-the-field harvesting is being performed. Cellphire's product is expected to have a 12 month shelf life and be immediately available for infusion after adding sterile water.

"We are excited about the addition of Dr. Peake to the Cellphire Board," said Cellphire President Mike Fitzpatrick. "With his incomparable experience and tireless commitment to providing the best possible care for the active duty uniformed services and veterans, we feel sure his contributions will help us achieve our goal."

Dr. Peake is a retired U.S. Army Lieutenant General; he was selected as the U.S. Army Surgeon General. After retirement from the Army he served as the Executive Vice President and Chief Operating Officer of Project Hope and most recently as the Secretary of the U.S. Department of Veterans Affairs. A native of St. Louis and graduate of the U.S. Military Academy at West Point, Peake attended medical school after serving in Vietnam with the 101st Airborne Division, where he was awarded the Silver Star
'/>"/>

SOURCE Cellphire, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus
2. Former EPA official calls for new environmental and consumer protection agency
3. Cliff Consulting, Inc. Adds Former Banking IT Executive Ashok Moorthy to Its Team
4. Former GE Healthcare Director, Per Foss Appointed CEO for HUNT Biosciences
5. Pepscan Achieves a Breakthrough With CLIPS Immunogen Technology: Synthetic Peptide Antigen is Able to Induce Fully Functional Antibodies Against a Formerly Intractable GPCR Target CXCR7
6. Lakewood-Amedex, Inc. Appoints William J. Robison, Former Executive Vice President of Pfizer, as Board Member
7. Former President of Sports Cardiology Consultants, LLC Christine Lawless, MD, MBA, ABCL, FACC, FACSM, Named Medical Director of CME Enterprise
8. Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
9. Former SADMERC Medical Directors Join OrthoCare Innovations as Medical and Scientific Advisory Board Members and Strategic Advisors
10. Cyntellect Appoints Former Millipore and BD Biosciences Executives to Head Up its Product Marketing Efforts
11. Cyntellect Appoints Former BD Biosciences Executive Andre Lubarsky as Director of Sales - North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... CARLOS, Calif. , May 28, 2015 /PRNewswire/ ... testing, today announced a study published in ... the Panorama single-nucleotide polymorphism (SNP)-based non-invasive prenatal test ... the first trimester. A study ... that complete molar pregnancies occur in about 1 ...
(Date:5/28/2015)... BEACH, Fla. , May 28, 2015 ... supporting the anti-cancer potential of its growth hormone-releasing hormone ... at the 2015 ASCO Annual Meeting. The data ... target for Biscayne,s anti-cancer GHRH blockers, is present on ... status. These findings suggest that GHRH antagonists could have ...
(Date:5/28/2015)... Whitehouse Laboratories is excited to announce that ... with PTI Inspection Systems. Whitehouse Labs and PTI will ... method development and validation programs using the most ... includes a more formal program that facilitates cross training ... enables a more effective team approach, especially as it ...
(Date:5/28/2015)... 2015 Clinerion, an eClinical ... and the Alliance for Clinical Research Excellence ... organization operating in the public interest and ... enhance quality, safety, integrity and operational effectiveness ... are pleased to announce their partnership for ...
Breaking Biology Technology:First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 3Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3Whitehouse Labs Renews & Enhances Partnership with PTI Inspection Systems 2Whitehouse Labs Renews & Enhances Partnership with PTI Inspection Systems 3Clinerion and ACRES Partner on Patient Recruitment and Risk-Based Quality Management 2Clinerion and ACRES Partner on Patient Recruitment and Risk-Based Quality Management 3
... by Launch of Nine Emerging Therapies, Including Five Oral Agents, According ... ... Resources, WALTHAM, Mass., May 29 Decision Resources, one of the,world,s ... highly anticipated launch of the first,oral agents formally approved for multiple sclerosis ...
... Inc. (Nasdaq: MAPP ) today announced the appointment ... Vice President of Human,Resources., Mr. Rosa brings over ... recently, Mr. Rosa worked at Carl Zeiss Meditec, Inc. ... had held since May of,2002. He was an integral ...
... Incorporated,(Nasdaq: GPRO ) announced today that the Company ... specific molecular diagnostic test to detect,high-risk strains of the ... Assay has been CE marked and is currently available,for ... marking and launch of our APTIMA HPV Assay in ...
Cached Biology Technology:Oral Drug From Novartis/Mitsubishi Tanabe Will Capture the Largest Market Share of All Emerging Multiple Sclerosis Therapies in 2017 2MAP Pharmaceuticals Appoints Marco Rosa Vice President of Human Resources 2Gen-Probe Launches in Europe CE-Marked APTIMA(R) HPV Assay for Detection of Human Papillomavirus 2Gen-Probe Launches in Europe CE-Marked APTIMA(R) HPV Assay for Detection of Human Papillomavirus 3Gen-Probe Launches in Europe CE-Marked APTIMA(R) HPV Assay for Detection of Human Papillomavirus 4Gen-Probe Launches in Europe CE-Marked APTIMA(R) HPV Assay for Detection of Human Papillomavirus 5
(Date:5/18/2015)... May 18, 2015 Fingerprint Cards (FPC) ... FPC1025, FPC1145, FPC1155 and FPC1035 from one if its module ... and including Q3 2015 and the sensors will be used ... order values for 2015 hereby amount to 740 MSEK to ... of 140 MSEK and a number of smaller orders not ...
(Date:5/11/2015)... 2015 Curemark LLC, a privately held drug ... new Phase III double blind, randomized, placebo-controlled clinical trial ... on all children ages 3-8 with Autism. Previously, Curemark ... double blinded clinical trial for CM-AT in children ages ... digestive enzyme chymotrypsin. This new trial will help determine ...
(Date:5/5/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, reminds investors and media that  Mr. David ... CARTES SECURE CONNEXIONS AMERICA 2015, held in Washington ... three-day conference is organized into a series of nine session ... Global Fraud: Where is the Trust in Cyberspace? and ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... plants to treat their offspring for disease, research by biologists ... 6 in the journal Ecology Letters. "We ... plants, can reduce parasite infection in the monarchs," says Jaap ... "And we have also found that infected female butterflies prefer ...
... at the Gladstone Institute of Virology and Immunology (GIVI) have ... in the liver is required for the infectious activity of ... new strategy for treating the infection. More than 160 ... is available to prevent further spread of the disease. Current ...
... at the Georgia Institute of Technology and Emory University have ... material into the body to improve the treatment of inflammatory ... become a popular research area because of its potential therapeutic ... a living organism has been an obstacle. In the ...
Cached Biology News:Study finds monarch butterflies use medicinal plants to treat offspring for disease 2Gladstone scientists link hepatitis C virus infection to fat enzyme in liver cells 2Researchers develop oral delivery system to treat inflammatory bowel diseases 2Researchers develop oral delivery system to treat inflammatory bowel diseases 3
For mRNA Differential Display with three one-base anchored oligo-dT primers and rationally designed arbitrary 13mers. These kits feature the latest generation of isotopic mRNA Differential Display t...
Request Info...
... Panomer 9 oligodeoxynucleotides are ... labeled at the 5' ... Alexa Fluor dyes and ... assessing microarray spot morphology, ...
Topoisomerase I, isolated from wheat germ, is an enzyme capable of removing negative supercoils from covalently closed circular DNA (1)....
Biology Products: